Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab for COVID-19 treatment
NL-OMON55152Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of lanadelumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Radboud University Medical Center. Started Oct 2020; status: completed.
02
Drugs
lanadelumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON55152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55152.